We are still early in the evolution of the GLP-1 Receptor Agonist class of drugs. Always great to look ahead though -- and most of these drugs work in similar

We are still early in the evolution of the GLP-1 Receptor Agonist class of drugs. Always great to look ahead though -- and most of these drugs work in similar way, i.e. they are GLP1 + something else. I personally think we're going to see a huge rise in the use of drugs like Rybelsus that are much easier to manage (oral instead of an injection), especially if people feel that they just want some help, rather than need an intense dosage.